Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0171 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 0.736 |
Open | 0.7308 |
1-Year Change | 62.47% |
Day's Range | 0.7069 - 0.7308 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 24, 2024 | 0.7120 | -0.0251 | -3.41% | 0.7371 | 0.7378 | 0.7069 |
Dec 23, 2024 | 0.7360 | -0.0254 | -3.34% | 0.7614 | 0.7635 | 0.7188 |
Dec 20, 2024 | 0.7609 | 0.0039 | 0.52% | 0.7570 | 0.7962 | 0.7269 |
Dec 19, 2024 | 0.7613 | -0.0057 | -0.74% | 0.7670 | 0.7740 | 0.7439 |
Dec 18, 2024 | 0.7513 | -0.0656 | -8.03% | 0.8169 | 0.8369 | 0.7369 |
Dec 17, 2024 | 0.8250 | -0.0120 | -1.43% | 0.8370 | 0.8400 | 0.8109 |
Dec 16, 2024 | 0.8394 | 0.0125 | 1.51% | 0.8269 | 0.8863 | 0.8069 |
Dec 13, 2024 | 0.8528 | -0.0003 | -0.04% | 0.8531 | 0.8690 | 0.8169 |
Dec 12, 2024 | 0.8497 | -0.0076 | -0.89% | 0.8573 | 0.8870 | 0.8374 |
Dec 11, 2024 | 0.8630 | -0.0129 | -1.47% | 0.8759 | 0.8777 | 0.8301 |
Dec 10, 2024 | 0.8779 | -0.0035 | -0.40% | 0.8814 | 0.9076 | 0.8369 |
Dec 9, 2024 | 0.8798 | -0.0019 | -0.22% | 0.8817 | 0.9196 | 0.8670 |
Dec 6, 2024 | 0.8651 | -0.0018 | -0.21% | 0.8669 | 0.9036 | 0.8579 |
Dec 5, 2024 | 0.8655 | -0.0124 | -1.41% | 0.8779 | 0.8976 | 0.8619 |
Dec 4, 2024 | 0.8828 | -0.0291 | -3.19% | 0.9119 | 0.9175 | 0.8769 |
Dec 3, 2024 | 0.9021 | -0.0214 | -2.32% | 0.9235 | 0.9399 | 0.8979 |
Dec 2, 2024 | 0.9355 | -0.0314 | -3.25% | 0.9669 | 0.9803 | 0.9269 |
Nov 29, 2024 | 0.9719 | 0.0050 | 0.52% | 0.9669 | 1.0069 | 0.9669 |
Nov 27, 2024 | 0.9624 | 0.0385 | 4.17% | 0.9239 | 0.9969 | 0.9193 |
Nov 26, 2024 | 0.9030 | -0.0239 | -2.58% | 0.9269 | 0.9294 | 0.8969 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com